<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3667">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366063</url>
  </required_header>
  <id_info>
    <org_study_id>991919</org_study_id>
    <secondary_id>IRCT20200217046526N2</secondary_id>
    <nct_id>NCT04366063</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome</brief_title>
  <official_title>Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Respiratory Distress Syndrome (ARDS) is the major cause of death in the COVID-19&#xD;
      pandemic. In this trial, the safety and efficacy of Mesenchymal Stem Cells (MSC) for the&#xD;
      treatment of ARDS in COVID-19 patients will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory distress syndrome (ARDS) is the major cause of death in the COVID 19&#xD;
      infection pandemic. It is a devastating clinical condition, caused by an acute and diffuse&#xD;
      lung injury that requires management in the intensive care unit. It is caused by uncontrolled&#xD;
      inflammation that leads to severe pulmonary alveolar damage and capillary membrane leakage,&#xD;
      and progressive respiratory failure. There is no effective treatment for ARDS and the only&#xD;
      supportive care strategies are the mainstay of therapy. Mesenchymal stem cells (MSCs) have&#xD;
      high regenerative and immunomodulatory capacities. In preclinical research, ARDS, MSCs&#xD;
      modulate the inflammatory response, augment tissue repair, enhance pathogen clearance, and&#xD;
      reduce the severity of the injury, pulmonary dysfunction, and apoptosis. Moreover, many&#xD;
      studies have shown that the anti-inflammatory effects of MSCs can significantly reduce virus&#xD;
      (e.g., Influenza)-induced lung injury and mortality in animals. Since 2014 clinical trials&#xD;
      are using MSC from variable sources [bone marrow (BM), fat, and umbilical cord (UC)] in the&#xD;
      treatment of ARDS. Some of the clinical trials are ongoing and the final reports are not&#xD;
      reported. In all final reports, the safety of the application of MSC has been documented and&#xD;
      most of them implied improvement in mortality and decrease of morbidity. Moreover,&#xD;
      experimental studies have demonstrated that MSCs or their extracellular vesicles (MSCs-EVs)&#xD;
      significantly reduced lung inflammation and pathological impairment resulting from different&#xD;
      types of lung injury. Also, macrophage phagocytosis, bacterial killing, and the outcome are&#xD;
      improved. It is highly likely that MSCs-EVs have the same therapeutic effect on inoculation&#xD;
      pneumonia as MSCs themselves.&#xD;
&#xD;
      Critically ill coronavirus documented cases suspicious to ARDS (mild or moderate) will be&#xD;
      enrolled in the study. Our previous experiment (IRCT20200217046526N1) showed the safety of 3&#xD;
      injections of MSCs in patients with COVID-19. This multi-center trial will recruit 60&#xD;
      patients. All patients in all groups will receive conventional therapy for virus treatment&#xD;
      and supportive care for ARDS.&#xD;
&#xD;
      The patients allocated randomly to three groups:&#xD;
&#xD;
      Control (n=20). Patients will conventional therapy for virus treatment and supportive care&#xD;
      for ARDS will be used as control.&#xD;
&#xD;
      Intervention Group1 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), at Day 0&#xD;
      and Day 2 intravenously.&#xD;
&#xD;
      Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), at Day&#xD;
      0 and Day 2 plus two doses of extracellular vesicles (EVs) on Day 4 and Day 6 intravenously.&#xD;
&#xD;
      The clinical symptoms, pulmonary imaging, side effects, 28-days mortality inflammatory&#xD;
      factors, etc. will be evaluated during the 28 days follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2020</start_date>
  <completion_date type="Anticipated">December 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events assessment</measure>
    <time_frame>From baseline to day 28</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood oxygen saturation</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>Evaluation of Pneumonia Improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit-free days</measure>
    <time_frame>Up to day 8</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
    <time_frame>From baseline to day 14</time_frame>
    <description>Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory efficacy</measure>
    <time_frame>From baseline to day 7</time_frame>
    <description>increase in PaO2/FiO2 ratio from baseline to day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers concentrations in plasma</measure>
    <time_frame>At baseline, 7, 14, 28 days after the first intervention</time_frame>
    <description>Biochemical examination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Two MSC infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Group1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) intravenously plus Conventional treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two MSC infusion Plus two EVs infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100×10e6 (±10%), intravenously plus two doses of EVs plus Conventional treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell therapy protocol 1</intervention_name>
    <description>Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.</description>
    <arm_group_label>Two MSC infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell therapy protocol 2</intervention_name>
    <description>Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.</description>
    <arm_group_label>Two MSC infusion Plus two EVs infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmation of 2019-nCoV infection by RT-PCR&#xD;
&#xD;
          -  Diagnosis of ARDS according to the Berlin definition of ARDS&#xD;
&#xD;
          -  Requiring supplemental oxygen&#xD;
&#xD;
          -  Pneumonia that is judged by chest radiograph or CT&#xD;
&#xD;
          -  PaO2/oxygen absorption concentration (FiO2) ≤ 300MMHG&#xD;
&#xD;
          -  Pulmonary imaging shows that the focused progress &gt; 50% in 24-48 hours&#xD;
&#xD;
          -  Mild to Moderate 2019-nCoV pneumonia/ stay in the ICU &lt;48 hours&#xD;
&#xD;
          -  SOFA score between 2-3 point&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe allergies or allergies after 1st injection to stem cell preparations and their&#xD;
             components&#xD;
&#xD;
          -  Patients with a malignant tumor, other serious systemic diseases, and psychosis&#xD;
&#xD;
          -  Co-Infection of HIV, tuberculosis, influenza virus, adenovirus, and other respiratory&#xD;
             infection viruses&#xD;
&#xD;
          -  Patients with a previous history of pulmonary embolism&#xD;
&#xD;
          -  Be thought by researchers to be inappropriate to participate in this clinical study&#xD;
             (Expected deaths within 48 hours, uncontrolled infections)&#xD;
&#xD;
          -  Liver or kidney SOFA score of more than 3 points; combined with other organ failures&#xD;
             (need organ support), Stage 4 severe chronic kidney disease or requiring dialysis&#xD;
             (i.e. estimated glomerular filtration rate (eGFR) &lt; 30)&#xD;
&#xD;
          -  Pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar&#xD;
             proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial&#xD;
             pneumonia&#xD;
&#xD;
          -  Continuous use of immunosuppressive agents or organ transplants in the past 6 months&#xD;
&#xD;
          -  In vitro life support (ECMO, ECCO2R, RRT)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Uncontrolled underlying disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdol Hossein Shahverdi</last_name>
    <role>Study Chair</role>
    <affiliation>Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossein Baharvand, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Stem Cells Biology and Technology, Cell Science Research Center, Royan Institute for Stem Cells Biology &amp; Technology, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masoumeh Nouri</last_name>
    <phone>00982127635512</phone>
    <email>masoume.nouri2002@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hoda Madani</last_name>
    <phone>00982122518388</phone>
    <email>hoda62_m@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <zip>16635148</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masoumeh Nouri</last_name>
      <email>masoume.nouri2002@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hoda Madani</last_name>
      <email>hoda62_m@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hossein Baharvand, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>2019 Novel Coronavirus Pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Researchers and clinicians</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

